Healthy Control Clinical Trial
Official title:
Genetic Susceptibility TO Ozone-induced Bronchial Airway Inflammatory Responses In Humans
The principal purpose of this study is to identify hyper-responsive, responsive and non-responsive groups of healthy human subjects based on their airway neutrophilic response to ozone exposure, and to perform micro-array analyses on DNA collected from recovered airway cells to explore possible differences in gene expression profiles between the three groups
Sputum assessment day: Subjects meeting the required health status following the medical
screening will be provided with a verbal and written description of all experimental
procedures and possible risks involved in their participation. All subjects will be required
to provide written informed consent to participate in the study. The ability of subjects to
produce adequate induced sputum samples will also be determined. Therefore the subjects will
be asked to produce sputum following inhalation of hypertonic saline (3, 4 and 5%). Subjects
should be able to produce at least 50 mg of sputum (selected plug) per sample. Each sputum
sample must contain a total cell count of at least 100,000 cells, a differential cell count
containing less than 40% squamous epithelial cells, and cell viability of at least 50%, thus
minimizing variability in cell recovery and squamous cell contamination. Subjects who are
effective sputum producers will then be scheduled for a training session. Subjects may still
be excluded from the study if unable to perform adequate pulmonary function tests.
Training session: Training session will occur no less than 2 days prior to exposure
- Lung function tests, including spirometry and plethysmography (body box measurements).
- Introduction to the ozone exposure chamber.
- Instruction on how to use the treadmill, including a minute ventilation measurement to
reach the level of exercise required for the study.
- Nitric oxide measurement - this measures the amount of nitric oxide (NO) present in
expired air. An increased concentration of NO in exhaled air may be found in normal
persons with acute inflammation during upper respiratory tract infections and in
association with symptoms in patients with allergic rhinitis. Thus, measurement of the
concentration of NO in expired air may be useful as an indirect assessment of airway
inflammation. Lung production of NO will be measured by collection of a sample of
exhaled gas. Nasal production of NO will be measured directly by connecting a NO
analyzer sampling line to one nostril with the other nostril open to ambient air. During
the nasal measurement the subject will exhale through a cardboard, disposable tube with
a resistance in order to close the palate and prevent contamination of the nasal sample
with. The entire procedure should be completed in less than 15 minutes.
Exposure and testing protocol: Upon arrival at the laboratory, subjects' clinical health
status will be ascertained by medical personnel, including base line heart rate, blood
pressure, evaluation of respiratory symptoms (breath sounds) and general health. All female
subjects will be required to provide a menstrual cycle history and a urine sample will be
required for pregnancy testing. Each pregnancy test will be considered valid for 7 days.
Testing will be postponed if a subject exceeds previously established limits.
The 0.4 ppm ozone exposure will be conducted in an ozone exposure chamber. Each subject will
be exposed to ozone for 2 hours. During the exposure, subjects will perform four 15 minute
bouts of moderate exercise (minute ventilation or VE = 30 40 L/min) on a treadmill, each
separated by 15 minutes of seated rest. Before and after exposure, lung function and breath
sounds will be assessed for any signs of bronchial constriction. Venipuncture (as noted
above) will occur prior to exposure. Measurements of cardiorespiratory performance will be
obtained during each exercise period.
Approximately 4-6 hours following ozone exposure, venipuncture will occur. Subjects will
perform the sputum induction procedures described above with nebulized inhaled hypertonic
saline (3, 4 and 5%). The subject will remain under medical supervision until pulmonary
function (spirometry) returns to within 5% of pre-exposure baseline values before leaving the
laboratory. Approximately 24 hours after the ozone exposure, subjects will return to the
laboratory for lung function testing and sputum induction, in addition to a venous blood
sample.
At each time point (pre and post exposure, and 24 hours post exposure), blood will be drawn
from the vein in forearm into clinical lab tubes. During one of these blood draws the
additional 5ml will be drawn for genotyping. Plasma will be separated from 4 ml and frozen at
70 degrees C for future analysis of mediators of interest, such as cytokines, as well as
other systemic effects of ozone. The remaining blood will be assessed by whole blood assays
for markers of inflammatory and immune activation (CD11b, CD14, CD64, CD16, HLA-DR, CD45,
CD3, CD80, CD86) and function (phagocytosis and oxidative burst) by two colour flow
cytometry. RNA will be extracted from sputum inflammatory cells for microarray analysis,.
During the course of participation all subjects will be required to abstain from; ingestion
of Vitamins C and E, aspirin or any other anti-inflammatory medication, exposure to cigarette
smoke or other irritants. In addition, subjects will be asked to have nothing by mouth for 2
hours before sputum induction. They will be asked to arrive in the research lab NPO x 2 hours
on training day and post exposure day, and will have lunch on exposure day at a time that
will allow for the 2 hour NPO requirement.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213706 -
Effect of Whole Body Periodic Acceleration on Airway Endothelial Function
|
N/A | |
Not yet recruiting |
NCT03938207 -
Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
|
||
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Recruiting |
NCT06446856 -
EVEN - Effects of VR on Empathy for Nature in Patients With Psychosis and Depressive Disorders
|
||
Completed |
NCT03049709 -
Non-invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis
|
N/A | |
Recruiting |
NCT05683184 -
OMAR Opioid Use Disorder
|
Phase 1 | |
Recruiting |
NCT01730781 -
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
|
||
Recruiting |
NCT04421079 -
Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP)
|
Phase 1 | |
Completed |
NCT02995200 -
Quantification of Upper Extremity Use and Effects of Feedback in the Home Setting
|
N/A | |
Completed |
NCT04036669 -
Adipokines as Predictors of Foot Function, Pain, and Disability in Patients With Rheumatoid Arthritis
|
||
Completed |
NCT03443193 -
Periodization of Exercise Training in Patients With Coronary Heart Disease.
|
N/A | |
Completed |
NCT01392027 -
Biospecimens for Identification of Diseases of the Pancreas.
|
N/A | |
Active, not recruiting |
NCT04393558 -
Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms
|
||
Completed |
NCT03914599 -
Protective Genetic Factors Against Neurological Diseases
|
||
Recruiting |
NCT04895826 -
Computer-vision Aided Community Back Pain Physiotherapy Services
|